Remove 2012 Remove Therapy Remove Treatments
article thumbnail

Malignant Melanoma

First Derm

Alexander Börve In A Nutshell Common More than 200,000 US cases per year Requires medical diagnosis Symptoms: Abnormal growth in moles Color: Typically brown Location: Anywhere on the skin Treatment: Surgery, Chemotherapy Death Rate Incident Rate ICD-10: C43.9 Early treatment by surgical removal is important, as the cancer may be aggressive.

Surgery 98
article thumbnail

Median Nail Dystrophy

First Derm

Median-Nail-Dystrophy-Median-Nail-Dystrophy In A Nutshell Rare Often self-diagnosable Symptoms: Canal-like split extend from the cuticle to the tip of the nail Color: n/a Location: On the nail, especially the thumbnail Treatment: Discontinuation of activities that cause trauma on the nail ICD-10: L60.3 ICD-9: 703.8 What can I do? 2022.08.051.

article thumbnail

Pediatric Psoriasis: Characteristics of a Cohort at UCSF Spanning 2 Decades

The Dermatology Digest

Cordoro, MD, and Carmel Aghdasi, BA Data presented at the Society for Pediatric Dermatology: 2021 Annual Meeting is helping to advance knowledge on epidemiology, clinical features, comorbidities, and evolving treatment patterns for pediatric psoriasis. The study authors say more research is needed.

article thumbnail

Pediatric Psoriasis: Characteristics of a Cohort at UCSF Spanning 2 Decades

The Dermatology Digest

Cordoro, MD, and Carmel Aghdasi, BA Data presented at the Society for Pediatric Dermatology: 2021 Annual Meeting is helping to advance knowledge on epidemiology, clinical features, comorbidities, and evolving treatment patterns for pediatric psoriasis. The study authors say more research is needed.

article thumbnail

Ozempic vs Berberine: What's the Difference?

Aesthetics Advisor

History of Ozempic 2012: Semaglutide, the active ingredient in both Wegovy and Ozempic, was developed by Novo Nordisk. The treatment duration varied from 30 to 56 weeks in the majority of the trials. ( This drug requries weekly injections, and is intended to be used for the treatment of diabetes.

article thumbnail

PEDIATRICS INFANTILE HEMANGIOMAS

The Dermatology Digest

Insights on ulcerated infantile hemangiomas in the ß-blocker era With Esteban Fernández-Faith, MD “Although ß-blockers have been standard therapy for problematic infantile hemangiomas (IHs) for a number of years, ulceration continues to be a challenge in many patients with IHs. We have to consider that this is a retrospective study.

Therapy 36
article thumbnail

PEDIATRICS INFANTILE HEMANGIOMAS

The Dermatology Digest

Insights on ulcerated infantile hemangiomas in the ß-blocker era With Esteban Fernández-Faith, MD “Although ß-blockers have been standard therapy for problematic infantile hemangiomas (IHs) for a number of years, ulceration continues to be a challenge in many patients with IHs. We have to consider that this is a retrospective study.

Therapy 36